Literature DB >> 10823868

Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

J A Palmer1, R H Branston, C E Lilley, M J Robinson, F Groutsi, J Smith, D S Latchman, R S Coffin.   

Abstract

Herpes simplex virus (HSV) has often been suggested as a suitable vector for gene delivery to the peripheral nervous system as it naturally infects sensory nerve terminals before retrograde transport to the cell body in the spinal ganglia where latency is established. HSV vectors might therefore be particularly appropriate for the study and treatment of chronic pain following vector administration by relatively noninvasive peripheral routes. However parameters allowing safe and efficient gene delivery to spinal ganglia following peripheral vector inoculation, or the long-term expression of delivered genes, have not been comprehensively studied. We have identified combinations of deletions from the HSV genome which allow highly efficient gene delivery to spinal dorsal root ganglia (DRGs) following either footpad or sciatic nerve injection. These vectors have ICP34.5 deleted and have inactivating mutations in vmw65. We also report that peripheral replication is probably necessary for the efficient establishment of latency in vivo, as fully replication-incompetent HSV vectors allow efficient gene expression in DRGs only after peripheral inoculation at a high virus dose. Very low transduction efficiencies are otherwise achieved. In parallel, promoters have been developed that allow the long-term expression of individual or pairs of genes in DRGs by using elements from the latently active region of the virus to confer a long-term activity onto a number of promoters which otherwise function only in the short term. This work further defines elements and mechanisms within the latently active region that are necessary for long-term gene expression and for the first time allows multiple inserted genes to be expressed from HSV vectors during latency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823868      PMCID: PMC112048          DOI: 10.1128/jvi.74.12.5604-5618.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells.

Authors:  T D Palella; L J Silverman; C T Schroll; F L Homa; M Levine; W N Kelley
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

Authors:  A T Dobson; T P Margolis; F Sedarati; J G Stevens; L T Feldman
Journal:  Neuron       Date:  1990-09       Impact factor: 17.173

3.  Analysis of the 2-kilobase latency-associated transcript expressed in PC12 cells productively infected with herpes simplex virus type 1: evidence for a stable, nonlinear structure.

Authors:  E Rødahl; L Haarr
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.

Authors:  D A Leib; D M Coen; C L Bogard; K A Hicks; D R Yager; D M Knipe; K L Tyler; P A Schaffer
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure.

Authors:  S L Deshmane; N W Fraser
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression.

Authors:  C I Ace; T A McKee; J M Ryan; J M Cameron; C M Preston
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control.

Authors:  S Forss-Petter; P E Danielson; S Catsicas; E Battenberg; J Price; M Nerenberg; J G Sutcliffe
Journal:  Neuron       Date:  1990-08       Impact factor: 17.173

8.  A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

9.  Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence.

Authors:  A R MacLean; M ul-Fareed; L Robertson; J Harland; S M Brown
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

10.  Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expression in the absence of trans-induction by Vmw65.

Authors:  M McFarlane; J I Daksis; C M Preston
Journal:  J Gen Virol       Date:  1992-02       Impact factor: 3.891

View more
  22 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

3.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 4.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 5.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

6.  Construction and characterization of a herpes simplex virus type I recombinant expressing green fluorescent protein: acute phase replication and reactivation in mice.

Authors:  John W Balliet; Anna S Kushnir; Priscilla A Schaffer
Journal:  Virology       Date:  2007-01-17       Impact factor: 3.616

7.  Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.

Authors:  Yoshitaka Miyagawa; Pietro Marino; Gianluca Verlengia; Hiroaki Uchida; William F Goins; Shinichiro Yokota; David A Geller; Osamu Yoshida; Joseph Mester; Justus B Cohen; Joseph C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

8.  Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression.

Authors:  Fang Han; Yoshitaka Miyagawa; Gianluca Verlengia; Selene Ingusci; Marie Soukupova; Michele Simonato; Joseph C Glorioso; Justus B Cohen
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 9.  Gene therapy for the treatment of diabetic neuropathy.

Authors:  Marina Mata; Munmun Chattopadhyay; David J Fink
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

10.  Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery.

Authors:  Chris Towne; Marie Pertin; Ahmed T Beggah; Patrick Aebischer; Isabelle Decosterd
Journal:  Mol Pain       Date:  2009-09-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.